Cure My Disease

Don't miss your cure!

 Log in / Sign up

Does drug particle size matter? a study puts prifetrastat to the test

NCT ID NCT07721402

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study is testing whether changing the particle size of the experimental drug prifetrastat affects how much of it enters the bloodstream. Healthy volunteers will receive a single dose of prifetrastat in one of several tablet formulations with different particle sizes, then after a break, a second dose of a different formulation. By comparing blood levels, researchers hope to learn whether particle size influences drug absorption, processing, and elimination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prifetrastat tablets with different particle sizes
What this could lead to
If particle size does not affect absorption, it could simplify manufacturing of prifetrastat. If it does, the results could guide future formulation development.
What could go wrong
This is a very early Phase 1 study with only 32 healthy participants, so results may not predict effects in patients or with repeated dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion * Females of non-childbearing potential and males \>=18 years of age at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECGs. * BMI of 18-32 kilogram per meter square(Kg/m\^2); and a total body weight \>50 kg (110 lb). Exclusion * Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention * Prior use of epigenetic modifying agents. Participants will only be permitted to enroll in a single arm of this study (cannot participate in Arm 1 and Arm 2). * Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s). * current use or anticipated need for food or drugs that are known strong inducers or inhibitors of CYP2C9 or CYP3A4, including their administration within 14 days plus 5 half-lives of the strong inducers or inhibitors of CYP2C9 or CYP3A4, whichever is longer, prior to first dose of study intervention, during the treatment period, and within 2 days after the last dose of prifetrastat * Proton pump inhibitors must be discontinued at least 14 days prior to the first dose of study medication and throughout treatment period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy participant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pfizer Clinical Research Unit - Brussels

    RECRUITING

    Brussels, Bruxelles-capitale, Région de, B-1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.